NX-5948 Combination for Chronic Lymphocytic Leukemia

This trial tests a new treatment for individuals with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Researchers aim to evaluate the effectiveness of NX-5948, a potential new drug, when combined with other drugs like venetoclax and sometimes an anti-CD20 antibody (rituximab or obinutuzumab). The goal is to discover better options for those who have tried other treatments without success or are beginning treatment for the first time. Suitable candidates have CLL or SLL requiring treatment, particularly if previous treatments included a Bruton tyrosine kinase inhibitor and were ineffective. As a Phase 1, Phase 2 trial, this research focuses on understanding the treatment's effects in people and measuring its effectiveness in an initial, smaller group, offering a chance to be among the first to benefit from new treatment options.

The trial protocol does not specify if you must stop taking your current medications, but you cannot have taken an investigational agent or anticancer therapy within 14 days before starting the study treatment.

Research has shown that NX-5948, also known as bexobrutideg, is generally well tolerated by patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Studies have found that even with longer treatment durations and higher doses, patients did not encounter major safety issues. Similarly, venetoclax, a medication already approved for CLL, has demonstrated a good safety record in various clinical trials.

When combined with rituximab, another approved drug, venetoclax has achieved high success rates. Although there are some risks, such as neutropenia (a low white blood cell count), it is generally considered safe. Obinutuzumab, when used with venetoclax, has shown similar safety and effectiveness in studies.

Unlike the standard treatments for Chronic Lymphocytic Leukemia (CLL), which often include chemotherapy and targeted therapies like ibrutinib and acalabrutinib, the combination involving NX-5948 offers something new. NX-5948 targets a specific protein involved in the survival of CLL cells, potentially offering a more precise attack on the cancer. Researchers are particularly excited about combining NX-5948 with venetoclax, a drug that helps trigger cancer cell death, and either rituximab or obinutuzumab, which are antibodies that further enhance the immune response against cancer cells. This multi-targeted approach could result in more effective and potentially quicker responses compared to existing therapies.

Research has shown that the combination of NX-5948 and venetoclax, one of the treatment arms in this trial, is promising. Specifically, 69.2% of patients with chronic lymphocytic leukemia (CLL) experienced a reduction or disappearance of their cancer. Venetoclax often pairs with other treatments because it helps stop cancer cells from growing, potentially improving survival rates. Another treatment arm in this trial includes rituximab, a medicine that targets specific proteins on cancer cells, which may enhance this effect by slowing or stopping cancer growth. Similarly, the trial includes an arm with obinutuzumab, another medicine targeting these proteins, which significantly lowered the risk of disease progression or death when used with venetoclax. Together, these treatments show strong potential to effectively fight CLL.²³⁶⁷⁸